Construction Partners, Inc. has acquired S.E. Cline Construction, a Florida-based company specializing in site development and underground utility construction. This acquisition adds about 60 employees and a hot-mix asphalt plant near Bunnell, Florida, to Construction Partners' Florida platform, C.W. Roberts Contracting. The move strengthens their presence along the rapidly growing Interstate 95 corridor and complements existing asphalt paving operations, positioning the company for further growth and integration in the region.
Construction Partners, Inc. acquisition news is presented here with relevant market data for context. For readers following Industrials-sector US stocks, 46 out of 135 priced stocks rose while 88 fell. Notable price changes include PLUG at USD 1.39 with a -6.40% change and an 82% buy order activity, QXO at USD 10.17 down 6.35%, and JBLU at USD 2.97 down 5.71% with 100% buy orders, as of Oct 20, 2026 03:01 WIB.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
